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Dose selection in chronic rodent bioassays
has been the focus of a great deal of atten-
tion and debate since the 1960s (1-5). A
particularly contentious issue has been
selection of the highest dose (typically the
maximum tolerated dose; MTD) in car-
cinogenicity assays (6). In the 1960s, when
chronic animal bioassays were first used
routinely to evaluate chemicals, the primary
objective was to assess the qualitative poten-
tial for toxicity and carcinogenicity. For this
purpose, the highest dose was selected to
elicit a toxic but not life-threatening effect
in a relatively small number ofanimals.
With the advent of formal risk assess-
ment methods in the late 1970s and early
1980s, studies that were originally intended
to assess the potential for toxicity or carcino-
genicity qualitatively were used to quantify
adverse impacts; that is, to estimate the
shape and slope of the dose-response curve
(7). Despite changes in interpretation and
use ofdata from chronic bioassays as well as
improvements in our understanding of the
mechanisms bywhich chemicals may induce
cancer, criteria for dose selection (particular-
ly the highest dose) have remained remark-
ably constant (2,7-11).
Differences in dose selection procedures
that exist between many developed countries
have also been problematic, particularly
where differences have led to increased
potential for trade barriers as a result ofrejec-
tion ofdata from chronic bioassays designed
to meet the requirements ofone country and
submitted for regulatory purposes in another
(12). The International Conference on
Harmonization (5) has agreed on several
options for selecting the highest dose in
chronic bioassays for pharmaceuticals; how-
ever, no such consensus exists for pesticides,
industrial chemicals, food additives, and
other nonpharmaceutical chemicals.
In 1993, the ILSI Risk Science Institute
formed a working group on dose selection
for chronic animal bioassays as one of the
activities under its cooperative agreement
with the EPA Office ofPesticide Programs.
Recognizing the dissatisfaction with current
approaches to dose selection, the goal ofthe
working group was to improve the testing
ofchemicals for long-term toxicity and car-
cinogenicity through appropriate dose
selection and to work toward international
harmonization ofdose selection procedures
for chronic bioassays. The working group
included scientists from academia, industry,
and government representing the United
States, Canada, Europe, andJapan.
This article sets forth a set ofprinciples
for dose selection in chronic rodent bioas-
says. The principles, which represent the
consensus of working group members,
encourage a move away from sole reliance
on an MTD as it has been traditionally
defined (primarily by body weight and
histopathology) and toward the use of
sound scientific and toxicologic principles
for the selection of the highest as well as
lower doses in the chronic bioassay. The
principles do not, however, address the
number of doses (typically three plus a
control) in a chronic bioassay. Increasing
the number of doses beyond three plus a
control may shed light on the shape and
slope ofthe dose-response curve; however,
there is general resistance to increasing the
number of doses because of cost con-
straints. Further, doses selected for chronic
studies may depend on or be influenced by
species, strain, route and mode ofadminis-
tration, diet, and other factors, and there
are critically important issues associated
with the interpretation ofresults ofchronic
bioassays in the context of risk assessment.
Despite the importance of these issues, the
principles developed by the working group
and presented in this paper focus solely on
dose selection for chronic rodent bioassays.
Principles for Dose Selection
Principle #1
Dose selection for chronic studies must be
based on sound toxicologic principles, e.g.,
see Klaassen et al. (13). Within a reasonable
dose range, increasing the dose can increase
the ability to detect an effect; therefore,
doses for chronic rodent bioassays should
be selected within this range to maximize
the sensitivity of a chronic bioassay.
However, trying to increase studysensitivity
by increasing doses into ranges that do not
reflect application of sound toxicologic
principles could lead to results that are
inappropriate for human risk assessment.
Increasing the highest dose in a chronic
bioassay may increase sensitivity within
some defined dose range, but the potential
exists that different mechanisms of toxicity
or chemical modes of action are active at
higher doses, which may not be relevant to
humans exposed to lower doses. The work-
ing group encourages an approach to dose
selection that incorporates all relevant infor-
mation from prechronic studies and other
sources, uses a wide range of toxicologic
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tools to understand the mechanisms or
modes of action by which a chemical pro-
duces an effect (e.g., genotoxicity, cell pro-
liferation, etc.), and uses good scientific
principles to enhance the accuracy ofjudg-
ments ofpotential human risks.
Principle #2
Scientists who conduct chronic bioassays and
those who use data from bioassays, induding
regulatory agencies, should encourage innov-
ative approaches to dose selection by consid-
ering appropriate study designs, mechanistic
data, and other information in the design
and interpretation of studies. Use of addi-
tional endpoints and other information must
be based on sound scientific rationale, and
such designs should be evaluated based on
their individual merits.
A goal ofhigh dose selection in carcino-
genicity bioassays is, in the context ofhaz-
ard identification, to reduce the likelihood
ofa false negative result; however, it is rec-
ognized that the qualitative nature of the
hazard (e.g., carcinogenic response) may
itself be dose dependent. This principle
encourages approaches to dose selection
that incorporate consideration of mecha-
nistic and other toxicologic information.
Such approaches should improve the scien-
tific basis for dose selection and aid in
interpretation of data generated from
chronic bioassays.
Principle #3
Selection of the middle and lower doses
should take into account factors, such as the
mechanism or mode ofaction, toxicokinet-
ics, and others listed in Principles #4 and
#5, and should not be based solely on a
fraction of the highest dose. Further, the
middle and lowest doses should be selected
to characterize the shape of the
dose-response curve as much as possible.
Human exposure should also be considered
in dose selection, particularly for the selec-
tion ofthe middle and lowest doses.
For substances expected to exhibit a
toxicity threshold, or if the evaluation of
carcinogenic potential is being combined
with an evaluation of chronic toxicity, the
study should be designed to include one
dose that does not elicit adverse effects, i.e.,
one dose should be a no observed adverse
effect level (NOAEL). Of course, caution
must be exercised to ensure that the
NOAEL is not simply an artifact of small
sample size or poorstudy design.
Where human exposure influences dose
selection, issues that should be considered
include the exposure route and mode, the
dose range in the chronic bioassay in rela-
tion to human exposure, and the duration
and frequency of human exposure, if
known. Subpopulations that may be more
highly exposed than the general popula-
tion, or that are genetically more suscepti-
ble, should also be considered.
Principle #4
The working group recommends the use of
innovative approaches and endpoints and
other information in the selection ofdoses
for chronic rodent bioassays. The following
endpoints, which can be assessed in
prechronic studies, should be considered in
dose selection for chronic rodent bioassays.
Histopathology. The site, morphology,
and severity ofthe treatment-related effects
observed in prechronic studies are critical
in dose selection. Histopathologic examina-
tion oftissues, especially the liver, gastroin-
testinal tract, urinary tract, respiratory
tract, skin, spleen/bone marrow/blood, and
endocrine tissues is recommended.
Toxicokinetics. Consideration of the
effect of dose (or exposure concentration)
on absorption, tissue distribution, metabo-
lism, and clearance of a compound is rec-
ommended.
Cellular growth. Information on the
dose-dependence ofregenerative cell prolif-
eration, induced mitogenesis, and apopto-
sis will be a useful adjunct to histological
observations in determining the shapes of
organ-specific toxic response curves; such
information will be of significant value in
selecting high, middle, and low doses, and
in interpreting the results ofthe study.
Physiologicalfunction. Disturbances of
physiology or homeostasis that would com-
promise the validity of the study must be
considered in the dose selection process.
Examples include hypotension, inhibition
of blood clotting, overwhelming normal
pulmonary clearance mechanisms, immune
system effects, and, in some cases, hormon-
al imbalance.
Clinicalchemistry, hematology, anduri-
nalysis. These endpoints are best used to
support dose selection decisions based on
other criteria/parameters. Changes in serum
clinical chemistry in the absence of
histopathologic observations may not affect
high dose selection, but may complement
dose selection decisions based on toxicoki-
netics, cell proliferation, and other parame-
ters. However, when hematological tissues
are determined to be a target organ in
prechronic studies, hematology results may
be an appropriate basis for dose selection.
Organ weights. This endpoint is not
often the critical factor in the selection of
doses for chronic rodent bioassays.
Chemically induced changes in organ
weights should, however, be considered in
conjunction with other data in the dose
selection process.
Body weight. Ifbodyweight changes are
the primary factor in the selection of the
highest dose group (that is, when no other
toxic effects are observed in prechronic
studies), a decrement in body weight gain
ofno more than 5-10% in prechronic stud-
ies should be used in the selection of the
highest dose for chronic assays of carcino-
genicity.
While many ofthese endpoints are not
presently assessed in typical prechronic
studies, it will be necessary to begin to
gather such data so that dose selection may
draw from a greater base of toxicologic
data. It should also be recognized that not
all ofthese endpoints may be useful or nec-
essary for every compound and that other
endpoints, where they are based on sound
toxicologic principles, may provide impor-
tant information for dose selection.
Principle #5
Physicochemical factors (e.g., solubility,
vapor pressure), the bioavailability of the
compound, the palatability of the com-
pound in food or drinkingwater, and other
factors such as the potential for the sub-
stance to cause adverse effects at the site of
administration (e.g., irritation, erosion, and
ulceration) will influence the selection of
the highest dose for chronic rodent bioas-
says. It is recommended that doses for
chronic rodent bioassays be selected to
minimize or avoid adverse nutritional,
physical, organoleptic, and irritant effects.
Conclusions
These principles do not provide detailed
instructions for dose selection. Rather, they
encourage the selection ofdoses that maxi-
mize study sensitivity and concurrendy pro-
duce results that are biologically and toxico-
logically credible. The working group
agreed that, at the completion ofthe bioas-
say, one should look retrospectively at the
doses that were selected and the data gener-
ated at those doses. Data obtained from
doses that are inconsistent with the princi-
ples presented above may not be appropri-
ate for use in human health risk assessment.
Implementation of these principles will
have two important benefits. First, imple-
mentation will improve the qualityand con-
sistency as well as the interpretation and uti-
lization of data from the rodent bioassay,
our most important tool to assess the long-
term toxicity and carcinogenicity of chemi-
cals, leading to a better assessment ofhuman
risk. Second, international harmonization of
dose selection procedures will reduce the
potential for trade barriers that may occur as
a result ofrejection ofdatadesigned to meet
the requirements of one country and sub-
mitted forregulatory purposes in another.
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